SLC35A2: A Potential Drug Target for Cancer and Other Diseases

Target Name: SLC35A2

NCBI ID: G7355

SLC35A2

SLC35A2: A Potential Drug Target for Cancer and Other Diseases

SLC35A2 (UDP-Gal-Tr) is a protein that is expressed in various tissues and cells in the body. Its function is not well understood, but it is known to be involved in the regulation of cell adhesion and migration. UDP-Gal-Tr has been identified as a potential drug target and has been shown to play a role in a variety of diseases, including cancer.

SLC35A2 is a member of the SLC family of proteins, which are known to be involved in the transfer of electrical signals within cells. UDP-Gal-Tr is a type of UDP-Gal excipient, which is used to label proteins for various applications, including biochemical studies and imaging. Gal-Tr is a modified version of the protein Galectin-3, which is a natural glycoprotein that is expressed in various tissues and cells.

SLC35A2 has been shown to play a role in the regulation of cell adhesion and migration. This is because it is involved in the formation of tight junctions, which are specialized junctions that form between epithelial cells. tight junctions are important for maintaining the integrity of the intercellular space and for ensuring that cells stick together to form tissues.

SLC35A2 is also involved in the regulation of cell migration. This is because it is able to interact with the protein vimentin, which is a major component of the cytoskeleton. This interaction between SLC35A2 and vimentin allows the protein to regulate the movement of cells in the direction of the cytoskeleton.

SLC35A2 has also been shown to be involved in the regulation of cell survival. This is because it is able to interact with the protein p53, which is a well-known tumor suppressor protein. This interaction between SLC35A2 and p53 allows the protein to regulate the activity of p53 and to prevent it from causing cell death.

In addition to its role in cell regulation, SLC35A2 has also been shown to play a role in the development and progression of cancer. This is because it is often overexpressed in various tissues and cells, which can lead to the formation of tumors. Additionally, SLC35A2 has also been shown to play a role in the regulation of the angiogenesis, which is the process by which new blood vessels are formed in response to the growth of a tumor.

Given the involvement of SLC35A2 in the regulation of cell adhesion, migration and survival, it is a potential drug target. Many studies have shown that blocking SLC35A2 function can inhibit the growth and progression of various cancers, including breast, ovarian, and colorectal cancers. Additionally, in addition to its potential cancer-related applications, SLC35A2 has also been shown to have potential applications in the treatment of other diseases, including diabetes, neurodegenerative diseases, and autoimmune disorders.

In conclusion, SLC35A2 is a protein that is involved in the regulation of cell adhesion, migration and survival. Its function is not well understood, but it is known to play a role in the regulation of these processes. Given its potential involvement in the development and progression of cancer, SLC35A2 is a potential drug target. Further research is needed to fully understand its role and to develop effective treatments for this disease.

Protein Name: Solute Carrier Family 35 Member A2

Functions: Transports uridine diphosphate galactose (UDP-galactose) from the cytosol into the Golgi apparatus, functioning as an antiporter that exchanges UDP-galactose for UMP (PubMed:9010752, PubMed:12682060). It is also able to exchange UDP-galactose for AMP and CMP, and to transport UDP-N-acetylgalactosamine (UDP-GalNAc) and other nucleotide sugars (PubMed:12682060, PubMed:11784306). As a provider of UDP-galactose to galactosyltransferases present in the Golgi apparatus, it is necessary for globotriaosylceramide/globoside (Gb3Cer) synthesis from lactosylceramide (PubMed:30817854)

The "SLC35A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets